OXIPLAT 100MG INJECTION contains Oxaliplatin which belongs to the group of medicine called Anticancer drugs. It is used to manage cancers of the colon and/or rectum. It is highly used in combination with other anti-cancer medicines (such as 5-flurouracil and folinic acid) as an adjunct to manage stage III colon cancer after removing the primary tumour. It can also be used to manage metastatic colorectal cancer (cancer of colon and rectum that has been spread to other parts of the body).
Before receiving OXIPLAT 100MG INJECTION inform your doctor if you have any liver, kidney or heart problems. You must also inform your doctor if you have low white blood count in your blood or recently received or planning to receive any vaccination in the upcoming days.
OXIPLAT 100MG INJECTION is not recommended for use in pregnant or breastfeeding women and in children aged below 18 years. Men and women receiving OXIPLAT 100MG INJECTION must use a suitable contraceptive method to avoid pregnancy while undergoing therapy with OXIPLAT 100MG INJECTION.
The most common side effects of receiving OXIPLAT 100MG INJECTION are tingling and numbness of body parts, abnormal sensation in the throat, nausea, vomiting, stomach pain, headache, dizziness, tiredness, weight loss, changes in taste, skin rash, hair loss, mouth ulcers and low blood calcium levels. Contact your doctor if any of these side effect worsens.
It is used to manage:
OXIPLAT 100MG INJECTION is an anticancer medication. It works by damaging the DNA (genetic material) of the cancer cells. As a result, it reduces abnormal growth and multiplication of cancer cells in the body.
OXIPLAT 100MG INJECTION will be given to you only by a doctor or a nurse into a vein (as an intravenous infusion).
Your doctor will decide the correct dose and duration of therapy for you depending upon your age, body weight and disease condition.
| Batch | 12 |
| Brand Name | Oxiplat |
| Company Name | Sun Pharmaceutical Industries Ltd |
| Expiry Date | 12/12/2024 |
| Factory Location | Sun Pharma Advanced Research Centre (SPARC), Tandalja, Vadodara – 390012, Gujarat, INDIA. Tel. : (91-265) 661 5500 Fax : (91-265) 235 4897 |
